U.S. markets closed

BiondVax Pharmaceuticals Ltd. (BVXV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.2300+0.0400 (+1.25%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close3.1900
Bid3.2200 x 800
Ask3.2400 x 1100
Day's Range3.1000 - 3.3500
52 Week Range2.3500 - 62.0000
Avg. Volume948,669
Market Cap37.233M
Beta (5Y Monthly)2.64
PE Ratio (TTM)N/A
EPS (TTM)-2.2960
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est81.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Why BiondVax Pharmaceuticals Stock Imploded Today
    Motley Fool

    Why BiondVax Pharmaceuticals Stock Imploded Today

    Investors sold off shares of the biopharmaceutical company after it reported negative results from a phase 3 clinical trial. BiondVax Pharmaceuticals is developing a potential stand-alone universal flu vaccine, M-001. In a pivotal clinical trial, the company tested M-001's safety and efficacy at reducing flu illness and severity.

  • /C O R R E C T I O N -- BiondVax Pharmaceuticals Ltd./
    PR Newswire

    /C O R R E C T I O N -- BiondVax Pharmaceuticals Ltd./

    BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a pioneer in the development of a universal flu vaccine designed to provide protection against current, future, seasonal and pandemic influenza, today announced topline data from the Company's pivotal, phase 3 clinical trial of M-001 as a standalone universal flu vaccine candidate.

  • BiondVax Announces At-The-Market (ATM) Equity Offering Program
    PR Newswire

    BiondVax Announces At-The-Market (ATM) Equity Offering Program

    BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the Phase 3 clinical trial M–001 universal influenza vaccine candidate ("BiondVax" or the "Company"), today announced it has entered into an agreement with BofA Securities as lead sales agent, and Citigroup and Credit Suisse as participating sales agents (collectively, the "Agents"), related to a $100 million At-The-Market (the "ATM Program") equity offering program pursuant to a prospectus supplement filed today with the Securities and Exchange Commission (the "SEC").